Treatment Clinical Trials for Small Cell Lung Cancer

Clinical trials are research studies that involve people. The clinical trials on this list are for small cell lung cancer treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 26-50 of 96

  • Nivolumab, Ipilimumab, and Plinabulin in Treating Patients with Recurrent Extensive Stage Small Cell Lung Cancer

    This phase I / II trial studies the side effects and best dose of plinabulin when given together with nivolumab and ipilimumab and to see how well they work in treating patients with extensive stage small cell lung cancer that has come back. Plinabulin blocks tumor growth by targeting both new and existing blood vessels going to the tumor as well as killing tumor cells. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving plinabulin with nivolumab and ipilimumab may work better in treating patients with extensive stage small cell lung cancer compared to standard chemotherapy.
    Location: 5 locations

  • ADI-PEG 20, Gemcitabine Hydrochloride and Docetaxel in Treating Patients with Unresectable or Metastatic Soft Tissue Sarcoma, Osteosarcoma, Ewing’s sarcoma, or Small Cell Lung Cancer

    This phase II trial studies how well pegargiminase (ADI-PEG 20) works in combination with gemcitabine hydrochloride and docetaxel in treating patients with soft tissue sarcoma, osteosarcoma, Ewing's sarcoma, or small cell lung cancer that cannot be removed surgically (unresectable) or that has spread to other parts of the body (metastatic). ADI-PEG 20 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ADI-PEG 20 with gemcitabine hydrochloride and docetaxel may work better in treating patients with soft tissue sarcoma.
    Location: 4 locations

  • BI 894999 First in Human Dose Finding Study in Advanced Malignancies

    The aim of the phase Ia (dose escalation) part of this trial is to assess-> determine the Maximum Tolerated Dose (MTD) using a continuous dosing schedule A, using an intermittent Schedule B (2 weeks on, one week off in 3-week cycles) and the MTD using an intermittent Schedule C (one week on followed by one week off treatment, repeated every two weeks in 4-week cycles) in patients with solid tumours. In the phase Ib expansion part, the aim is to further evaluate the safety profile of BI 894999 at the dose recommended by the data monitoring committee (DMC). Once the MTD has been determined for both schedules A and B in patients with solid tumours, the MTD will be determined as well in patients with diffuse large B-cell lymphoma (DLBCL), using the DMC recommended schedule for solid tumours
    Location: 4 locations

  • Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients

    A Phase 1 / 2 open label trial of intravenous administration of TAEK-VAC-HerBy vaccine in patients with advanced HER2- expressing cancer. The study will be completed in 3 stages. In Stage 1 patients will be enrolled and treated according to a 3+3 dose escalation scheme. Up to 4 dose levels will be explored. Stage 2 will enroll patients with HER2- positive breast and gastric cancer to administer the TAEK-VAC-HerBy vaccine in combination with HER2 antibodies. Stage 3 will enroll patients to evaluate the safety and tolerability of the TAEK-VAC-HerBy vaccine in combination with HER2 antibodies and PD-1 / PD-L1 antibody. Patients, in all three stages, will receive TAEK-VAC-HerBy every three weeks, three administrations in total.
    Location: 4 locations

  • Guadecitabine and Carboplatin in Treating Patients with Extensive Stage Small Cell Lung Cancer

    This phase II trial studies how well guadecitabine and carboplatin work in treating patients with small cell lung cancer that has spread outside of the lung in which it began or to other parts of the body (extensive stage). Guadecitabine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving guadecitabine and carboplatin may work better in treating patients with extensive stage small cell lung cancer compared to other standard of care chemotherapy drugs.
    Location: 3 locations

  • FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

    FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance. The preclinical data provide compelling evidence supporting the clinical investigation of FT500 as monotherapy and in combination with ICI in subjects with advanced solid tumors.
    Location: 3 locations

  • A Dose Escalation and Expansion Study of RO7121661, a PD-1 / TIM-3 Bispecific Antibody, in Participants With Advanced and / or Metastatic Solid Tumors

    This is a first-in-human, open-label, multicenter, Phase I multiple-ascending dose (MAD) study of single agent RO7121661, an anti PD-1 (programmed death-1) and TIM-3 (T-cell immunoglobulin and mucin domain 3) bispecific antibody, for participants with advanced and / or metastatic solid tumors. The study consists of 2 parts: Dose Escalation (Part A) and Expansion (Parts B1, B2, B3, B4, and B5). The Dose Escalation part will be conducted first to determine the maximum tolerated dose (MTD) and / or recommended dose for expansion (RDE) based on safety, tolerability, pharmacokinetic, and / or the pharmacodynamic profile of escalating doses of RO7121661. The Expansion part will enroll tumor-specific cohorts to evaluate anti-tumor activity of the MTD and / or RDE of RO7121661 from Part A (Q2W) and to confirm safety and tolerability in participants with selected tumor types. Recruitment into the Expansion Part B4: SCLC Cohort is now closed.
    Location: 3 locations

  • A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and / or Refractory Solid Tumors

    An open-label, dose-escalation (Part 1), dose-expansion (Part 2) study to assess the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-155 alone and in combination with paclitaxel or docetaxel. In Part 1 (dose escalation), participants will receive escalating doses of ABBV-155 monotherapy (Part 1a) or ABBV-155 in combination with paclitaxel or docetaxel (Part 1b). In Part 2 (dose expansion), participants will receive ABBV-155 monotherapy or in combination therapy. The ABBV-155 monotherapy cohort will enroll participants with relapsed or refractory (R / R) small cell lung cancer (SCLC) (Part 2a); the ABBV-155 plus a taxane (paclitaxel or docetaxel) combination cohort will enroll participants with R / R non-small cell lung cancer (NSCLC) and breast cancer (Part 2b).
    Location: 6 locations

  • Testing the Safety of M6620 (VX-970) When Given with Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases from Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors

    This phase I trial studies the side effects and best dose of berzosertib (M6620 [VX-970]) when given together with whole brain radiation therapy in treating patients with non-small cell lung cancer, small cell lung cancer, or neuroendocrine tumors that have spread from the original (primary) tumor to the brain (brain metastases). Berzosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving berzosertib together with radiation therapy may work better compared to standard of care treatment, including brain surgery and radiation therapy, in treating patients with non-small cell lung cancer, small cell lung cancer, or neuroendocrine tumors.
    Location: 5 locations

  • Study of Combination APG-1252 Plus Paclitaxel in Patients With Relapsed / Refractory Small Cell Lung Cancer

    A Multi-Center, Phase Ib / II Study of Combination APG-1252 plus Paclitaxel in Patients with Relapsed / Refractory Small Cell Lung Cancer (SCLC)
    Location: 4 locations

  • A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors

    To determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended Phase 2 dose (RP2D) of FF-10850 (topotecan liposome injection) in patients with advanced solid tumors.
    Location: 3 locations

  • Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

    The primary objective of this study is to determine the safety and tolerability of pamiparib, the maximum tolerated dose (MTD) or maximum administered dose (MAD) for pamiparib combined with TMZ, to select the recommended Phase 2 dose (RP2D) and schedule of pamiparib in combination with TMZ, and to determine the antitumor activity of pamiparib in combination with TMZ.
    Location: 3 locations

  • Stereotactic Radiosurgery in Treating Patients with Oligometastatic Disease

    This phase II trial studies how well stereotactic radiosurgery works in treating patients with cancer that has spread to 5 or fewer places in the body and involves 3 or fewer organs (oligometastatic disease). Stereotactic radiosurgery, also known as stereotactic body radiation therapy, is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue.
    Location: 3 locations

  • Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced / Metastatic Solid Tumors

    A multicenter open-label phase 1 / 1b study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced / metastatic solid tumors
    Location: 2 locations

  • Talazoparib and Low-Dose Temozolomide in Treating Patients with Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

    This phase II trial studies how effective talazoparib and temozolomide are for treating patients with extensive-stage small cell lung cancer that has come back after an initial chemotherapy treatment. Talazoparib, a PARP inhibitor, may stop the growth of tumor cells by preventing them from repairing their DNA. Chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving talazoparib and temozolomide may work better in treating patients with extensive-stage small cell lung cancer than either one alone.
    Location: 2 locations

  • Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer

    GTI-4419-203 will be an open-label, multi-center study to evaluate GC4419 administered intravenous (IV) for the reduction of radiation induced esophagitis in subjects receiving chemoradiotherapy for unresectable Stage 3A / 3B or post-operative Stage 2B NSCLC, SCLC treatable with chemoradiotherapy.
    Location: 2 locations

  • A Study of ZN-c3 in Participants With Solid Tumors

    This is a Phase 1 / 2 open-label, multicenter study, evaluating the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics of ZN-c3 alone and in combination with other drugs.
    Location: 2 locations

  • A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

    This trial will study ladiratuzumab vedotin (LV) to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur. A side effect is anything the drug does besides treating cancer.
    Location: 2 locations

  • Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

    To evaluate the safety and tolerability of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers. Patients will be followed long-term for Overall Survival (OS) and safety. The study will enroll approximately 90 patients and maximum study treatment duration is approximately 2.13 years.
    Location: 2 locations

  • Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors

    Prospective, open-label, dose-ranging, uncontrolled phase I study with PM01183 in combination with irinotecan to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM01183 in combination with irinotecan in patients with selected advanced solid tumors.
    Location: 2 locations

  • Stereotactic Radiosurgery for the Treatment of Patients with Small Cell Lung Cancer Brain Metastasis

    This phase II trial investigates how stereotactic radiosurgery affects brain functions while treating patients with small cell lung cancer that has spread to the brain (brain metastasis). Standard of care treatment consists of whole brain radiation therapy, which targets the entire brain, and may result in side effects affecting the nervous system. Stereotactic radiosurgery only targets areas of the brain that are suspected to be affected by the disease. The purpose of this trial is to learn if and how patients’ brain functions are affected by the use of stereotactic radiosurgery rather than whole brain radiation therapy in managing brain metastasis caused by small cell lung cancer. Stereotactic radiosurgery may help patients avoid nervous system side effects caused by whole brain radiation therapy.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Vorolanib and Atezolizumab for the Treatment of Extensive-Stage Small Cell Lung Cancer

    This phase II trial investigates how well vorolanib and atezolizumab work in treating patients with extensive-stage small cell lung cancer. Vorolanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving vorolanib with atezolizumab may control or reduce the return (recurrence) of the cancer after standard chemotherapy treatment.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • Intensity-Modulated Proton Therapy in Treating Patients with Limited Stage or Extensive Stage Small Cell Lung Cancer

    This trial studies the side effects of intensity-modulated proton therapy in treating patients with limited stage or extensive stage small cell lung cancer. Radiation therapy such as intensity-modulated proton therapy uses high energy protons to kill tumor cells and shrink tumors. Intensity-modulated proton therapy may be able to precisely target the tumor and reduce the damage to nearby healthy tissue.
    Location: Emory University Hospital / Winship Cancer Institute, Atlanta, Georgia

  • NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

    The main purposes of Phase 1b of this study are to determine the following in participants with advanced solid tumors: - Safety and tolerability of NT-I7 in combination with pembrolizumab - Maximum Tolerated Dose (MTD) and / or the Recommended Phase 2 Dose (RP2D) The main purpose of Phase 2a of this study is to assess the preliminary anti-tumor activity of NT-I7 in combination with pembrolizumab in participants with checkpoint inhibitor (CPI) treated and naïve relapsed and refractory tumors.
    Location: 2 locations

  • Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

    The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors
    Location: 2 locations